Londoño, M.C.García-Buey, L.Mallolas, J.Barril, GuillerminaAhumada, A.Riveiro-Barciela, M.Muñoz-Gómez, R.Roget, M.Serra, M.A.Devesa, M.J.Navascues, C.Baliellas, CarmeAldamiz-Echevarría, T.Gutiérrez, M.L.Carmona, I.Polo Lorduy, B.Bonet, L.García-Samaniego, J.Jiménez, M.Prieto Castillo, MartínMoran, S.Castro-Iglesias, ÁngelesDelgado, M.Gea, F.Martín-Granizo, I.Montes, M.Morano, LuisCastaño, M.A.De los Santos, I.Laguno, M.Losa-García, Juan E.Montero, M.Rivero, A.Manzanares, A.De Álvaro, C.2019-01-302019-01-302017Londoño MC, García-Buey L, Mallolas J, Barril G, Ahumada A, Riveiro-Barciela M,et al. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study [abstract]. J Hepatol. 2017;66(Suppl 1):S718-S719. Abstract nº SAT-226.0168-8278http://hdl.handle.net/2183/21635Poster presentationengCreative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC-BY-NC-ND 4.0)http://creativecommons.org/licenses/by-nc-nd/4.0/conference outputopen access